Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis

Megan Rossi, Kerenaftali Klein, David W Johnson, Katrina L Campbell, Megan Rossi, Kerenaftali Klein, David W Johnson, Katrina L Campbell

Abstract

Objective. This paper assessed the effectiveness of pre-, pro-, and synbiotics on reducing two protein-bound uremic toxins, p-cresyl sulphate (PCS) and indoxyl sulphate (IS). Methods. English language studies reporting serum, urinary, or fecal PCS and/or IS (or their precursors) following pre-, pro-, or synbiotic interventions (>1 day) in human adults were included. Population estimates of differences in the outcomes between the pre- and the postintervention were estimated for subgroups of studies using four meta-analyses. Quality was determined using the GRADE approach. Results. 19 studies met the inclusion criteria, 14 in healthy adults and five in haemodialysis patients. Eight studies investigated prebiotics, six probiotics, one synbiotics, one both pre- and probiotics, and three studies trialled all three interventions. The quality of the studies ranged from moderate to very low. 12 studies were included in the meta-analyses with all four meta-analyses reporting statistically significant reductions in IS and PCS with pre- and probiotic therapy. Conclusion. There is a limited but supportive evidence for the effectiveness of pre- and probiotics on reducing PCS and IS in the chronic kidney disease population. Further studies are needed to provide more definitive findings before routine clinical use can be recommended.

Figures

Figure 1
Figure 1
Search methodology for the PCS and IS literature review.
Figure 2
Figure 2
Meta-analysis for pre-, pro-, and synbiotic therapy on serum IS in the HD population.
Figure 3
Figure 3
Meta-analysis for pre-, pro-, and synbiotic therapy on urinary PCS in the healthy population.

References

    1. Data WLCIP, editor. World Health Organisation. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2004.
    1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology. 2004;15(5):1307–1315.
    1. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in Uremia? Blood Purification. 2010;29(2):130–136.
    1. Meijers BKI, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. p-cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clinical Journal of the American Society of Nephrology. 2009;4(12):1932–1938.
    1. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. American Journal of Nephrology. 2007;27(1):30–35.
    1. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis. 2011;15(2):120–124.
    1. Meijers BKI, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology Dialysis Transplantation. 2011;26(3):759–761.
    1. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney International. 2009;76(supplement 114):S12–S19.
    1. Evenepoel P, Claus D, Geypens B, et al. Amount and fate of egg protein escaping assimilation in the small intestine of humans. American Journal of Physiology. 1999;277(5):G935–G943.
    1. Lin CJ, Chen HH, Pan CF, et al. p-cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. Journal of Clinical Laboratory Analysis. 2011;25(3):191–197.
    1. Gibson G, Scott K, Rastall R. Dietary Prebitoics: current status and new defintion. IFIS Functional Foods Bulletin. 2010;7(1):1–19.
    1. National Health and Medical Research Council Guideline Assessment Register Consultants. NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines. N.H.A.M.R. Council; 2009.
    1. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney International. 2006;70(12):2058–2065.
    1. Wishart DS, Tzur D, Knox C, et al. Human Metabolome Database. Canada: Genome Alberta & Genome; 2009.
    1. Vanholder R, Bammens B, De Loor H, et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation. 2011;26(5):1464–1467.
    1. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2011.
    1. Viechtbauer W. Conducting meta-analyses in R with the metafor. Journal of Statistical Software. 2010;36(3):1–48.
    1. Cloetens L, Broekaert WF, Delaedt Y, et al. Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study. British Journal of Nutrition. 2010;103(5):703–713.
    1. De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K. Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects. Alimentary Pharmacology and Therapeutics. 2008;27(6):504–513.
    1. Ito M, Kimura M, Deguchi Y, Miyamori-Watabe A, Yajima T, Kan T. Effects of transgalactosylated disaccharides on the human intestinal microflora and their metabolism. Journal of Nutritional Science and Vitaminology. 1993;39(3):279–288.
    1. Ito M, Deguchi Y, Matsumoto K, Kimura M, Onodera N, Yajima T. Influence of galactooligosaccharides on the human fecal microflora. Journal of Nutritional Science and Vitaminology. 1993;39(6):635–640.
    1. Terada A, Hara H, Kataoka M, Mitsuoka T. Effect of lactulose on the composition and Metabolic Activity of the Human Faecal Flora. Microbial Ecology in Health and Disease. 1992;5(1):43–50.
    1. Geboes KP, De Hertogh G, De Preter V, et al. The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. British Journal of Nutrition. 2006;96(6):1078–1086.
    1. Alles MS, Hartemink R, Meyboom S, et al. Effect of transgalactooligosaccharides on the composition of the human intestinal microflora and on putative risk markers for colon cancer. American Journal of Clinical Nutrition. 1999;69(5):980–991.
    1. Ling WH, Korpela R, Mykkanen H, Salminen S, Hanninen O. Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. Journal of Nutrition. 1994;124(1):18–23.
    1. Tohyama K, Kobayashi Y, Kan T. Effect of lactobacilli on urinary indican excretion in gnotobiotic rats and in man. Microbiology and Immunology. 1981;25(2):101–112.
    1. Fujiwara S, Seto Y, Kimura A, Hashiba H. Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. Journal of Applied Microbiology. 2001;90(3):343–352.
    1. De Preter V, Coopmans T, Rutgeerts P, Verbeke K. Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects. Journal of the American College of Nutrition. 2006;25(6):541–549.
    1. De Preter V, Geboes K, Verbrugghe K, et al. The in vivo use of the stable isotope-labelled biomarkers lactose-[15N]ureide and [2H4]tyrosine to assess the effects of pro- and prebiotics on the intestinal flora of healthy human volunteers. British Journal of Nutrition. 2004;92(3):439–446.
    1. De Preter V, Vanhoutte T, Huys G, et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. American Journal of Physiology. 2007;292(1):G358–G368.
    1. Swanson KS, Grieshop CM, Flickinger EA, et al. Fructooligosaccharides and Lactobacillus acidophilus modify bowel function and protein catabolites excreted by healthy humans. Journal of Nutrition. 2002;132(10):3042–3050.
    1. Meijers BKI, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. P-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology Dialysis Transplantation. 2010;25(1):219–224.
    1. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. American Journal of Kidney Diseases. 2003;41(3):S142–S145.
    1. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. Journal of Renal Nutrition. 2005;15(1):77–80.
    1. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oval administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74(2):349–355.
    1. Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrology Dialysis Transplantation. 2011;26(3):1094–1098.
    1. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. American Journal of Clinical Nutrition. 2004;80(6):1536–1543.
    1. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney International. 2003;64(6):2196–2203.
    1. Cummings JH, Hill MJ, Bone ES. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. American Journal of Clinical Nutrition. 1979;32(10):2094–2101.
    1. Geypens B, Claus D, Evenepoel P, et al. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut. 1997;41(1):70–76.
    1. Ling WH, Hanninen O. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. Journal of Nutrition. 1992;122(4):924–930.
    1. Lee CT, Kuo CC, Chen YM, et al. Factors associated with blood concentrations of Indoxyl sulfate and p-Cresol in patients undergoing peritoneal dialysis. Peritoneal Dialysis International. 2010;30(4):456–463.
    1. Vitetta L, Sali A. Probiotics, prebiotics and gastrointestinal health. Medicine Today. 2008;9(9):65–70.
    1. Sutton D, Dumbleton S, Allaway C. Can increased dietary fibre reduce laxative requirement in peritoneal dialysis patients? Journal of Renal Care. 2007;33(4):174–178.
    1. Wang HF, Lim PS, Kao MD, Chan EC, Lin LC, Wang NP. Use of isomalto-oligosaccharide in the treatment of lipid profiles and constipation in hemodialysis patients. Journal of Renal Nutrition. 2001;11(2):73–79.
    1. Den Hond E, Geypens B, Ghoos Y. Effect of high performance chicory inulin on constipation. Nutrition Research. 2000;20(5):731–736.
    1. Hasler CM. Functional foods: their role in disease prevention and health promotion. Food Technology. 1998;52(11):63–70.
    1. Campbell KL, Ash S, Bauer JD, Davies PSW. Evaluation of nutrition assessment tools compared with body cell mass for the assessment of malnutrition in chronic kidney disease. Journal of Renal Nutrition. 2007;17(3):189–195.
    1. Heimbürger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. American Journal of Kidney Diseases. 2000;36(6):1213–1225.
    1. Campbell K, Campbellm K, MacLaughlin H, et al. Evidence based practice guidelines for the nutritional management of chronic kidney disease. Nutrition & Dietetics. 2007;63(supplement 2):S33–S45.
    1. Mitsubishi Tanabe Pharma Corporation. A Study of AST-120 For Evaluating Prevention of Progression in Chronic Kidney Disease (EPPIC-1) 2011.
    1. Nakamura T, Kawagoe Y, Matsuda T, et al. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney and Blood Pressure Research. 2004;27(2):121–126.
    1. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology. 2011;6(1):30–39.
    1. Sanaka T, Akizawa T, Koide K, Koshikawa S. Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis. Therapeutic Apheresis. 2003;7(2):269–278.
    1. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Therapeutic Apheresis and Dialysis. 2007;11(3):189–195.
    1. Yorioka N, Ito T, Masaki T, et al. Dose-independent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure. Journal of International Medical Research. 2002;30(5):467–475.
    1. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney International, Supplement. 1997;51(63):S188–S190.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa